NEW ORLEANS, Dec. 15, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 22, 2017 to file lead plaintiff applications in a securities class action lawsuit against Skechers U.S.A., Inc. (NYSE:SKX), if they purchased the Company’s shares between April 23, 2015 and October 22, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Get Help
Skechers investors should visit us at https://www.claimsfiler.com/cases/view-skechers-usa-inc-securities-litigation-2 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Skechers and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On October 22, 2015, the Company released its Q3 2015 results, which revealed net sales far below analysts’ consensus estimates based on $20 million in net sales being moved from Q3 to Q2 2015 because of early customer deliveries as well as a weaker retail environment than expected.
On this news, the price of Skechers shares plummeted $14.55 per share, or 31.50 percent, to close on October 23, 2015 at $31.64 per share.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 



